Healthcare Security Policy Sub-Forum of 2021 China Conference on Rare Diseases Successfully Held
On Nov. 9th and 10th, 2021, the R&D-based Pharmaceutical Association Committee (RDPAC) held virtual “Global R&D Leaders Webinars”.
the press conference "Joining Together – Building a New Future for China's Pharma Innovation Ecosystem" was held at the 4th China International Import Expo (CIIE).
A major requisite for innovation is integrity, which is also the foundation of reputation. Without ethical decision-making, there is no true innovation.
The R&D-based Pharmaceutical Association Committee (RDPAC) has announced a change in membership of the RDPAC Executive Committee 2022-2023.
The 2022 Jinling Pharmoeconomics Forum and the Annual Conference of Pharmoeconomics Committee, Jiangsu Pharmaceutical Association were held online on April 16-17.
The R&D-based Pharmaceutical Association Committee (RDPAC) announces its new Chairman and Vice Chairmen for RDPAC Executive Committee 2022-2023.
Beijing, September 24, 2021 – The R&D-based Pharmaceutical Association Committee (RDPAC) announces a great news on its newly-elected Executive Committee Members for 2022-2023.
Through joint efforts of PhIRDA and RDPAC, the “Fostering China Pharmaceutical Innovation System Report 4: Promote Simultaneous R&D, Registration and Review of Innovative Drugs” is officially released today.
On 16th August, the 3rd sub-report of Fostering China Pharmaceutical Innovation System: Multi-layered Healthcare Security System to Improve People's Health and Drive High-quality Industrial Development was released through joint efforts by PhIRDA and RDPAC
PhRMA and RDPAC, together with EFPIA, JPMA and BIO, co-hosted the annual Joint China Strategy Sessions on Science/Regulatory, Intellectual Property and Market Access.
On the occasion of the Two Sessions, China Association of Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee (RDPAC) released the Report on Innovation in Pharmaceutical Industry for a Healthy China
Heads of RDPAC’s 24 multinational pharmaceutical companies in China, on behalf of the pharmaceutical industry, called upon the government, businesses, universities, and research institutes to cooperate, improve relevant policies and strengthen their implementation from diverse areas and to bring practical benefits to patients in China.
On March 2, 2021, PhIRDA and RDPAC jointly released "Building China's Pharmaceutical Innovation Ecosystem-Part One of the series research reports: 2015-2020 Development Review and Future Prospects"
Chairman of the RDPAC Executive Committee, came to the RDPAC Beijing office to extend holiday greetings to all RDPAC staff.
On December 18, 2020, the annual meeting of RDPAC R&D Committee was grandly held on the Roche Pharma Shanghai campus.
The “Innovation and Collaboration for Healthy China” conference given by RDPAC was solemnly held in the Medical Devices and Medical Care exhibition area of the China International Import Expo.
On September 27, 2020, the 5th China BioMed Innovation and Investment Conference was held in Suzhou Industrial Park.
As the leader of global pharmaceutical innovation, RDPAC member companies will continue to show their global innovative achievements in the 3rd CIIE.
Recently, KANG Wei, Managing Director of R&D-Based Pharmaceutical Association Committee (RDPAC) received an exclusive interview from Chinese Pharmaceutical News on hot topics that she cared about during the two sessions.
Two sessions were finally held after the outbreak, at this special historical moment, the China leader of RDPAC 22 member companies have shared their views
R&D-Based Pharmaceutical Association Committee (RDPAC) and China Alliance of Rare Diseases (CHARD) have established a long-term partnership, and jointly initiated a research on Medical Insurance Access and Payment Mechanism and Impact on Basic Medical Insurance Fund of Rare Disease Drugs in China
April 15-21 this year is the 26th National Cancer Prevention and Control Week in China. The Bureau of Disease Prevention and Control of the National Health Commission (NHC) called on the whole society and the pharmaceutical industry, on the theme of “Joint Action for Cancer Prevention and Control”
In view of the current severe situation of COVID-19 in the world, the organizing committee has decided to cancel the International Pharmaceutical Innovation Forum 2020 (IPIF 2020).
As of March 12, 2020, more than 35 RDPAC member companies have donated cash and medical supplies with a total value of more than RMB 190 million
(Beijing, March 26, 2019) Today, key stakeholders and thought leaders in the pharmaceutical industry gathered in Beijing for the 2nd International Pharmaceutical Innovation Forum (IPIF19)
RDPAC releases Faces of Innovation: Meeting the Challenge of Chronic Respiratory Diseases report
On October 10, 2019, Kang Wei, Managing Director of RDPAC, gave a speech on the theme of “Code of Ethics for Pharmaceutical Industry - a Shi
RDPAC announced its interim Executive Committee Bureau.
Recognizing China’s growing status in global pharmaceutical innovation, IPIF19 will bring together public and private stakeholders from acro
[ Beijing, Feb 27, 2018] ---R&D-Based Pharmaceutical Association Committee (RDPAC) today announced that Madam KANG Wei will take the role of
Today, seven institutions jointly released the research report titled Deepening the drug innovation ecosystem reform -- A plan to design and
On December 14th, The R&D-based Pharmaceutical Association Committee (RDPAC) announced its new Executive Committee Members.
During the 26th “World Diabetes Day” approaching, RDPAC released 2017 report Meet the Challenges of Diabetes with Drug Innovation in Shangha
On 19 June 2017 Joe Damond, Executive Vice President of BIO, signed a Memorandum of Understanding for Cooperation (MOU) with Mr. Mike Dethic
We have just ended Two Sessions this year, where Premier Li Keqiang made special mention regarding the health of the people, and 2,000 repre
22 March 2017 –NANJING: Ten leading domestic and foreign trade associations signed and endorsed the Declaration for Pharmaceutical Innovatio
On January 19, a press conference for the 2017 International Pharmaceutical Innovation Forum (IPIF) was successfully held in Nanjing, China.
With the 16th “World Cancer Day” approaching on February 4, the R&D Based Pharmaceutical Association Committee of the China Association of
With the coming of the 25th “World Diabetes Day”, R&D Based Pharmaceutical Association Committee of China Association of Enterprises with Fo
Innovation-driven development is a core strategy of China’s “13th Five-Year (2016-2020) Plan” and biomedicine is a key driver of that innova
Tuesday June 28, 2016, Beijing: the 2016 Pharmaceutical Enterprises Ethical Business Practices China Forum jointly organized by 17 pharmaceu
“China Symposium for Pharmaceutical Industry Self-regulation and Career Management and Development of Medical Representatives” was held in B
The R&D-based Pharmaceutical Association Committee under the China Association of Enterprise with Foreign Investment (RDPAC) published the r
The 2015 China Forum on Ethical Business Practices for Pharmaceutical Enterprises jointly organized by nine pharmaceutical industry associat
The International Hospital Federation (IHF) and the International Generic Pharmaceutical Alliance (IGPA) endorse efforts by organizations re
To further promote the implementation of the Ethical Codes for Pharmaceutical Companies (hereinafter the Codes), strengthen the building of
A survey on 30 city- and county-level grass-roots medical institutions shows, after implementation of essential drug system, the average fee
At the 15th Environment, Health and Safety (EHS) Working Group Meeting held by R&D-based Pharmaceutical Association Committee of CAEFI (RDPA
Chinese Medical Doctor Association (CMDA) held a workshop on the survey results of “Cognition Degree of Clinicians on Specialization Degree
97 innovative medicines to treat type 1 and type 2 diabetes lies in the pipeline of RDPAC member companies with another 23 in development to
On October 20, 2010, the 13th Environment, Health and Safety Working Group Meeting was held by R&D-based Pharmaceutical Association Committe
R&D-based Pharmaceutical Association Committee of CAEFI (RDPAC) issues the “Pharmaceutical Quality Study Report”. For the purpose to make Ch
China, as a rapidly growing emerging economy, should give equal attention to the demand of offspring development while meeting the ever-incr
According to the statistical presentation of R&D-based Pharmaceutical Association Committee of CAEFI (RDPAC), among 37 RDPAC member companie
The National “Twelfth Five-Year Plan” for Drug Safety specifically states that drug safety is an issue that concerns people’s welfare and pu
Download by password (663KB)
Download by password (726kb)
Download by password (2.57MB)
Download by password (318kb)
Download (1.2 MB)
Copyright © 2011 RDPAC.org All Rights Reserved